Consumer health: what it means for the future of life sciences
How life sciences can choose to shape the critical layer in health value ecosystems, or risk ceding value to others in the era of consumer health
Consumer health as an operating reality
Health is increasingly managed as a continuous journey – across prevention, treatment, monitoring, lifestyle changes and ongoing disease management. As healthcare becomes more connected, value is increasingly created across a broader ecosystem of providers, pharmacies, diagnostics companies, insurers and technology players.
The industry's historical model remains highly effective at delivering scientific innovation. But many of today's growth drivers lie beyond the product itself. Consumer expectations, chronic disease, digital health, real-world evidence and new market entrants are changing how value is created and captured. Scientific innovation remains the foundation. Increasingly, however, influence sits in the layers around the product, where evidence, data, trust and engagement shape outcomes, decisions and economic value.
What kind of firm must a life sciences company become to remain relevant, credible, and economically powerful in the age of the consumer?
A different leadership challenge
The five forces making the historical model insufficient
Societal & behavioural pressure
Health optimisation is becoming a mass-market behavioural and economic reality, organised increasingly by consumer rather than clinical logic.
- The wellness economy reached USD 6.3 trillion in 2023, signalling that more health activity is being organised by consumer, not clinical, logic.1
- Populations are living longer but not necessarily spending more of those additional years in good health.2
- OECD PaRIS finds that 54% of adults live with two or more chronic conditions, and 29% with three or more.2
Scientific pressure
Innovation is increasingly creating value beyond the therapy alone.
- Categories such as GLP-1 show how biology, prevention, behaviour, and engagement are converging into one economic system.
- Combination therapies, advanced modalities, companion diagnostics, and therapy-service models increasingly turn the product into a broader health value ecosystem.
- As more value is created before diagnosis, between interventions, and after launch, the historical model of invent-approve-launch becomes less sufficient on its own.
Technological pressure
Digital health is becoming part of the infrastructure through which health is accessed, monitored and managed.3 Consumers already live inside always-on ecosystems of devices, apps, platforms, remote monitoring, and digital workflows.
- AI is also moving from experimentation to regulated capability, which means competitive advantage now depends not only on invention, but also on governed deployment, compliance, and operational trust.4
- Diagnostics is also moving closer to everyday life, becoming the signal layer through which many health journeys begin.5
Lifestyle & social-determinant pressure
Major disease burdens are increasingly shaped by behaviour, environment, adherence and daily-life conditions.
- Obesity is now a structural driver of demand across multiple categories, not an isolated issue.
- Mental health and cognition increasingly shape outcomes across disease areas through resilience, behaviour, engagement, and the ability to stay on therapy and navigate care.
- This shifts value toward players that can influence daily life, not only clinical events.
Geopolitical, regulatory & economic pressure
Volatility is becoming part of the operating baseline.
- Cyber regulation, AI regulation, privacy regulation, pharmaceutical reform, supply security, access pressures, and geopolitical fragmentation are increasingly shaping strategic freedom, cost structure, speed, and resilience.
- The implication is clear: firms are competing on more than solely product quality or scientific strength. They are competing on their ability to operate resilient, trusted, regulation-ready systems under continuous external pressure.
More than USD 300bn
What this means across key therapeutic areas
Consumer health is not a trend that affects every disease area in the same way. The degree of disruption differs significantly depending on the patient journey, the role of technology, the importance of behaviour change and the number of stakeholders involved in care.
Although the six disease clusters differ significantly, each represents a different stress test of the same enterprise challenge: the ability to operate coherent, regulated health value ecosystems across real patient and consumer journeys.
Cardiometabolic & lifestyle-driven
The rise of obesity, diabetes and cardiovascular disease is accelerating the shift towards continuous health management. Outcomes depend not only on treatment, but also on lifestyle, adherence, monitoring and long-term engagement. For life sciences companies, this creates opportunities to move beyond episodic interactions and participate in a patient's health journey over many years.
The strategic challenge is how to connect the therapy with data, coaching, monitoring and behavioural support to improve outcomes over time.
Oncology and survivorship
Cancer care is becoming increasingly personalised and data-driven. Advances in diagnostics and precision medicine continue to improve treatment decisions, while survivorship is becoming a growing focus as patients live longer after diagnosis. As a result, value extends far beyond the treatment phase.
Leaders should assess where they can create value across the broader oncology journey, from early detection and diagnostics to monitoring, survivorship and patient support. The greatest opportunities may lie in connecting these elements rather than addressing them separately.
Neurology, mental health and cognitive disorders
Many neurological and mental health conditions require long-term support rather than short-term intervention. Patient engagement, treatment adherence and ongoing monitoring often play a significant role in outcomes. Digital health solutions are also becoming more relevant in supporting patients between clinical interactions.
Success increasingly depends on understanding how people engage with care over time. Building trust, improving engagement and reducing friction throughout the patient journey can be just as important as scientific innovation.
Immune-mediated and chronic inflammatory diseases
Patients with chronic inflammatory conditions often require treatment over many years. Despite advances in therapy, many patients struggle with adherence, treatment persistence and disease management. This creates significant untapped potential to improve both outcomes and efficiency.
Organisations should look beyond treatment initiation and consider where support services, education, monitoring and patient engagement can create additional value throughout the treatment journey.
Rare diseases, cell and gene, and radioligand therapies
Advanced therapies have the potential to transform patient outcomes, but they also introduce operational complexity. Manufacturing, logistics, treatment coordination and reimbursement pathways often become critical success factors. In some cases, the surrounding infrastructure determines whether patients can access treatment at all.
In advanced therapies, success depends as much on coordinating complex care pathways as on the therapy itself. Leaders should view operational excellence as a strategic capability rather than a supporting function.
Infectious diseases and pandemic-type threats
Recent global health events have highlighted the importance of preparedness, resilience and public trust. Rapid response capabilities, effective partnerships and reliable supply chains are becoming increasingly important components of healthcare systems. Public confidence also plays a significant role in the success of prevention and treatment efforts.
Long-term success will require organisations to balance innovation with resilience, while maintaining trust with patients, healthcare professionals and wider society.
Rethinking growth and value creation
Historically, growth was driven primarily by scientific breakthroughs and product innovation. New sources of growth are emerging across the healthcare system. That means looking beyond the product to the evidence, data, engagement models and partnerships that increasingly shape how value is created and captured.
At the same time, other players are gaining influence over parts of the health journey that increasingly determine value, including access, data, navigation, engagement and customer relationships.
Leaders need to decide where they want to participate, which capabilities they need to control, and how they will remain relevant as value shifts across the healthcare ecosystem.
Consumer health – a blueprint for life sciences
Choosing your role in the future health ecosystem
There is no single path to success. Some organisations will seek to become ecosystem leaders, shaping the critical layers that influence how value flows across healthcare. Others will act as system partners or selective orchestrators, coordinating specific parts of the journey alongside other stakeholders. Others may deliberately remain high-value component suppliers, contributing specialist science, products or services within ecosystems shaped by others. All three positions can succeed when pursued deliberately.
The risk is not choosing one model over another. The risk is drifting into a weaker position by default while others shape the assets and relationships that increasingly determine value. The organisations best positioned for the future will be those that make deliberate choices today, build the right capabilities and strengthen their position within the ecosystem.
What leaders should consider
Be clear about where you can lead
Not every organisation needs to orchestrate an entire ecosystem. Focus on the areas where you can make a meaningful and differentiated contribution.
Partner without giving up the critical logic
Many future opportunities will require collaboration across healthcare, technology and data ecosystems. Partnerships will be essential, but companies still need clarity on the interfaces, data, economics and decision rights they need to shape.
Govern the assets and control points that create influence
Evidence, data, trust, engagement and journey logic are becoming increasingly important control points in health value ecosystems. Organisations should actively shape and govern these assets rather than leaving them to be shaped by others.
Align investments with your chosen role
Capabilities, partnerships and business models should follow the role the company has chosen – not accumulate as disconnected initiatives.
Consumer health is not a separate market or trend. It reflects a broader shift in how health is managed, delivered and experienced. The organisations best positioned for the future will be those that deliberately shape the parts of the health value ecosystem where they can create value and retain meaningful strategic influence.